OTCMKTS:PURE PURE Bioscience (PURE) Stock Price, News & Analysis → Forget the “Magnificent 7” Tech Companies, Buy This AI Stock Instead (From Banyan Hill Publishing) (Ad) Free PURE Stock Alerts $0.09 +0.02 (+28.88%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$0.07▼$0.1050-Day Range$0.07▼$0.1052-Week Range$0.06▼$0.17Volume42,100 shsAverage Volume32,403 shsMarket Capitalization$9.98 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort InterestStock AnalysisChartEarningsFinancialsHeadlinesSEC FilingsShort Interest Get PURE Bioscience alerts: Email Address Ad Weiss RatingsTiny AI projects with huge promise hiding in plain sight …I’ve developed a system that’s helped me find huge winners in the past. Now my system has alerted me to the next four altcoins that could be the next superstars.Click here to find out who they are. About PURE Bioscience Stock (OTCMKTS:PURE)PURE Bioscience, Inc. develops and commercializes antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control in the United States and internationally. The company manufactures and distributes silver dihydrogen citrate (SDC), a non-toxic antimicrobial agent, which offers residual protection, as well as formulates with other compounds. It offers SDC-based disinfecting and sanitizing products, including PURE Hard Surface, a food contact surface sanitizer and disinfectant; PURE Control, a food contact processing aid for fresh produce and raw poultry; PURE Multi-Purpose and Floor Cleaner Concentrate to clean various resilient surfaces, including floors, glass, and food contact surfaces; and PURE Multi-Purpose Hi-Foam Cleaner Concentrate to clean stainless steel equipment, resilient floors, walls, and painted surfaces. The company also provides Axen30, a hard surface disinfectant; Axenohl, an antimicrobial formulation for use as a raw material ingredient in the manufacturing of consumer and commercial disinfecting and sanitizing products; and SILVÉRION, an antimicrobial formulation that is used against bacteria, viruses, yeasts, and molds. PURE Bioscience, Inc. was incorporated in 1992 and is headquartered in Rancho Cucamonga, California.Read More PURE Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PURE Stock News HeadlinesMay 6, 2024 | morningstar.comKeymed Biosciences Inc 02162May 6, 2024 | businesswire.comPURE Bioscience Appoints Darin Zehr to Board of DirectorsMay 6, 2024 | finance.yahoo.comMikra Announces Joint Product with Jose BautistaMay 2, 2024 | msn.comEXCLUSIVE: Former Sprint CEO Dan Hesse On Going From Cleaning Sewers To Leading Billion-Dollar Tech CompaniesApril 29, 2024 | finance.yahoo.comVedanta Biosciences to Present at Upcoming Investor ConferencesApril 15, 2024 | finance.yahoo.comPURE Bioscience, Inc. (PURE)March 28, 2024 | msn.comScientists say they're closer to reviving Mammoths. What could go wrong?March 23, 2024 | msn.comSam Altman's mission to increase human lifespan with a $180 million shipping container experiment at Retro BiosciencesMarch 18, 2024 | businesswire.comPURE Bioscience Reports Fiscal Second Quarter 2024 Financial ResultsMarch 14, 2024 | yahoo.comAs European dynamism gathers momentum, Elaia and partners double down with new deep tech fundMarch 13, 2024 | finanznachrichten.deKuros Biosciences AG: Kuros Reports 163% Growth in Direct MagnetOs Sales and 153% Increase in Total Medical Device Sales for the Full Year 2023March 13, 2024 | markets.businessinsider.comKuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023March 7, 2024 | finance.yahoo.comMoligo Technologies Appoints John Kuijpers as Chief Business OfficerMarch 6, 2024 | finance.yahoo.comVedanta Biosciences to Host Investor Meetings at the Leerink Partners 2024 Global Biopharma ConferenceMarch 5, 2024 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria to Begin Diabetes and Weight Loss Animal Study WEIGHT-A24-1March 1, 2024 | thetimes.co.ukThe world’s most expensive honey and the sweet taste of successFebruary 29, 2024 | marketwatch.comAvidity Biosciences Shares Climb on $400 Million Private PlacementFebruary 22, 2024 | news.yahoo.comMajor economic growth legislation could lift acre limit and attract billion dollar companiesFebruary 22, 2024 | benzinga.comPURE Bioscience Stock (OTC:PURE), Analyst Ratings, Price Targets, PredictionsFebruary 22, 2024 | sg.finance.yahoo.comQ4 2023 Arcus Biosciences Inc Earnings CallFebruary 20, 2024 | finance.yahoo.comWILLOW BIOSCIENCES ANNOUNCES STRATEGIC INVESTMENT FROM KALSEC TO DEVELOP INNOVATIVE NATURAL FOOD INGREDIENTSFebruary 7, 2024 | msn.comCell Microsystems and OMNI Life Science Announce Strategic Partnership to Bring Innovative Cellular Analysis Solutions to North AmericaFebruary 6, 2024 | finance.yahoo.comNightHawk Biosciences Completes Name Change to Scorpius Holdings; Trading to Commence Under “SCPX” Effective at the Market Open TodayFebruary 1, 2024 | markets.businessinsider.comNightHawk’s Scorpius BioManufacturing Subsidiary Announces the Promotion of Joe Payne to President and Chief Operating OfficerJanuary 16, 2024 | finance.yahoo.comPresage Announces FDA Study May Proceed to Evaluate Pre-GMP Drug Candidate in CIVO Phase 0 Clinical TrialSee More Headlines Receive PURE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PURE Bioscience and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/18/2024Today5/16/2024Next Earnings (Estimated)6/12/2024Fiscal Year End7/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Miscellaneous chemical products Sub-IndustryN/A Current SymbolOTCMKTS:PURE CUSIPN/A CIK1006028 Webwww.purebio.com Phone(619) 596-8600Fax619-596-8790Employees11Year Founded1992Profitability EPS (Most Recent Fiscal Year)($0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-3,960,000.00 Net Margins-194.80% Pretax Margin-124.61% Return on Equity-717.03% Return on Assets-326.30% Debt Debt-to-Equity RatioN/A Current Ratio1.72 Quick Ratio1.59 Sales & Book Value Annual Sales$1.87 million Price / Sales5.34 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares111,860,000Free Float65,145,000Market Cap$9.98 million OptionableNot Optionable Beta0.17 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Robert F. Bartlett (Age 79)President, CEO & Director Comp: $129.8kMr. Mark Stuart Elliott (Age 49)VP of Finance and Principal Financial & Accounting Officer Comp: $180kMr. Thomas Richard Myers (Age 71)Executive VP of Technology & Development and Director Comp: $200kMr. Jeff KitchellVP of Operations & Corporate SecretaryMr. Tim SteffensmeierVice President of Sales & MarketingKey CompetitorsArtemis TherapeuticsOTCMKTS:ATMSCalidi BiotherapeuticsNYSEAMERICAN:CLDIGraybug VisionNASDAQ:GRAYCyclerion TherapeuticsNASDAQ:CYCNMedicureOTCMKTS:MCUJFView All Competitors PURE Stock Analysis - Frequently Asked Questions How have PURE shares performed in 2024? PURE Bioscience's stock was trading at $0.1297 on January 1st, 2024. Since then, PURE shares have decreased by 31.2% and is now trading at $0.0893. View the best growth stocks for 2024 here. Are investors shorting PURE Bioscience? PURE Bioscience saw a increase in short interest in the month of April. As of April 30th, there was short interest totaling 6,000 shares, an increase of 122.2% from the April 15th total of 2,700 shares. Based on an average daily volume of 55,600 shares, the short-interest ratio is presently 0.1 days. View PURE Bioscience's Short Interest. When is PURE Bioscience's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, June 12th 2024. View our PURE earnings forecast. How were PURE Bioscience's earnings last quarter? PURE Bioscience, Inc. (OTCMKTS:PURE) announced its earnings results on Monday, March, 18th. The company reported ($0.01) earnings per share for the quarter. The company had revenue of $0.33 million for the quarter. PURE Bioscience had a negative trailing twelve-month return on equity of 717.03% and a negative net margin of 194.80%. What other stocks do shareholders of PURE Bioscience own? Based on aggregate information from My MarketBeat watchlists, some companies that other PURE Bioscience investors own include NVIDIA (NVDA), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), Riot Platforms (RIOT), Enphase Energy (ENPH), Mastercard (MA), Main Street Capital (MAIN), Twilio (TWLO) and How do I buy shares of PURE Bioscience? Shares of PURE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:PURE) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportBiden to Drop BOMBSHELL June 13th?Paradigm PressRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldElon to Transform U.S. Economy? Porter & CompanyCharles Payne Demystifies OptionsUnstoppable ProsperityThe most important AI company you've never heard ofManward PressThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyWATCH: The Truth About InflationBirch Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PURE Bioscience, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.